Visible light-activatable platinum( iv ) prodrugs harnessing CD36 for ovarian cancer therapy
- 12 July 2023
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 52 (31) , 10942-10950
Abstract
Visible light-activatable Pt( iv ) prodrugs harness the upregulated CD36 to facilitate cell entry and killing of drug resistant ovarian cancer cells.Keywords
Funding Information
- Kent State University (PAA-0213)
- Kent State University (Healthy Communities Research Institute)
- Basic Energy Sciences (DE-SC0016501)
- National Cancer Institute (1R15CA249712-01A1)
This publication has 40 references indexed in Scilit:
- Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironmentScience Translational Medicine, 2016
- The problem with platinumNature, 2015
- Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drugNature Communications, 2015
- Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug DeliveryJournal of the American Chemical Society, 2014
- What do we know about the reduction of Pt(IV) pro-drugs?Journal of Inorganic Biochemistry, 2012
- Modular Approach toward Bioactive Fiber Meshes Carrying OligosaccharidesMacromolecules, 2010
- Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicineDalton Transactions, 2009
- A potent cytotoxic photoactivated platinum complexProceedings of the National Academy of Sciences, 2007
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Platinum(IV) antitumour compounds: their bioinorganic chemistryCoordination Chemistry Reviews, 2002